Medicines are not sweets: read the package leaflet and follow the instructions

European medicines authorities have joined forces in a campaign that uses joint messages to raise awareness about the proper use of over-the-counter (OTC) medicines. 

OTC medicines sold without a prescription are often used to treat mild and ordinary symptoms, such as aches and fever occurring in conjunction with colds.  All medicines, including OTC medicines, involve risks and they are only safe when used correctly according to the instructions. Incorrect use can lead to adverse effects or even addiction. 

“Key information about the medicine and instructions for its correct use can be found in the package leaflet that comes in the package. Always read the leaflet even if you are familiar with the medicine, and follow the instructions. You can also check the information in the leaflet in the FimeaWeb service,” says Director General Eija Pelkonen.

OTC medicines may cause undesirable adverse effects or interactions with other medicines that you are taking. 

“Information about adverse effects and interactions can also be found in the package leaflet. If necessary, you can ask a professional for advice at a pharmacy or in health care."

European medicines authorities are campaigning on behalf of responsible use of OTC medicines  

The ‘Medicines are not sweets’ campaign is the first joint communications campaign launched by the Heads of Medicines Agencies (HMA), and it uses joint messages in EU Member States. The campaign targets anyone who uses OTC medicines, such as painkillers, nasal sprays or cough syrups. 

Fimea is involved in the campaign on its social media channels. The campaign begins on 15 September 2025 and will continue through week 38. Publications are shared using the hashtag #MedicinesAreNotSweets.

The main messages of the campaign are:

• read the package leaflet
• only take OTC medicines according to the instructions and restrictions on use
• contact a doctor if your symptoms persist despite taking an OTC medicine. 

The Heads of Medicines Agencies (HMA) is a network of the leaders of the national competent authorities responsible for regulating medicines in EU Member States. HMA works in close cooperation with the European Medicines Agency (EMA) and the European Commission in processes related to pharmacovigilance and marketing authorisations for medicines. More information is available on the HMA website.